Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Non-small Cell Lung Cancer


 BACON
_________________________________________________________________
  bleomycin....... 30 U IV day 2, then weekly times 6 weeks.
  adriamycin...... 40 mg/sqm IV day 1, then every 4 weeks.
  lomustine....... 65 mg/sqm orally day 1, then every 8 weeks.
  vincristine..... 0.75 to 1.0 mg/sqm IV day 2, then weekly times 
                   6 weeks.
  mechlorethamine. 8 mg/sqm IV day 1, then every 4 weeks.
  FREQUENCY....... Specified above.


  reference...
    Livingston RB.  Fee WH.  Einhorn LH.  Burgess MA.  Freireich 
    EJ.  Gottlieb JA.  Farber MO. BACON (bleomycin, adriamycin, 
    CCNU, oncovin and nitrogen mustard) in squamous lung cancer. 
    Experience in fifty patients. Cancer.  37(3):1237-42, 1976 
    Mar. 
  abstract...
    Fifty patients with inoperable squamous carcinoma of the lung. 
    38 with extensive, and 12 with limited disease, were treated 
    with BACON. Tumor regression greater than 50% was observed in 
    17 patients (45%) with extensive, and four patients (33%) with 
    limited disease. Stabilization of disease for greater than or 
    equal to 8 weeks was seen in four extensive and eight limited 
    patients, and had the same prognostic importance with regard 
    to survival as response: in extensive disease, responding and 
    stable patients had median survival (MST) of 26 weeks from 
    start of therapy, while MST for non-responders was 9 weeks. 
    MST in limited disease (all patients responding or stable) was 
    32 weeks. Analysis of survival in extensive disease by 
    performance status showed improvement in each category over 
    historical control results for supportive care alone. BACON 
    was better tolerated and probably more effective when CCNU was 
    given every 8 weeks, rather than every 4 weeks. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.